Chan Frank 4
4 · HAEMONETICS CORP · Filed May 19, 2026
Research Summary
AI-generated summary of this filing
Haemonetics (HAE) COO Frank Chan Receives RSU Award
What Happened Frank Chan, Chief Operating Officer of Haemonetics Corporation (HAE), was granted 27,535 restricted stock units (RSUs) on May 15, 2026. To cover tax obligations on the vesting event, 546 shares were withheld/disposed at $56.29 per share, totaling $30,734. The RSUs are awards (code A) and the withholding is reported as tax withholding (code F).
Key Details
- Transaction date: 2026-05-15; filing date: 2026-05-19 (timely filing).
- Withheld shares: 546 shares withheld at $56.29/share for taxes — proceeds $30,734 (disposition code F).
- Award: 27,535 RSUs granted (acquisition code A); monetary value not stated in filing.
- Post-transaction holdings: filing indicates the RSUs plus previously reported unvested RSUs and ESPP purchases (139 shares on 2025-10-31 and 119 shares on 2026-04-30); total share count after the grant is not explicitly stated in the summary provided.
- Footnotes: F1 = withholding for tax obligations; F2 = includes previously reported unvested RSUs and two recent ESPP purchases (139 and 119 shares); F3 = RSUs vest 40%/40%/20% over three years; F4 = each RSU converts to one common share when vested.
Context
- RSU grants are compensation awards (not open-market purchases) and typically reflect company pay programs rather than an immediate bullish bet by the insider.
- The tax-withholding move is routine (covering tax liability upon grant/vesting) and should not be read as a standard "sale" for sentiment.
- Purchases (open-market buys) tend to be more directly informative of insider conviction; awards primarily reflect compensation policy and retention incentives.
Insider Transaction Report
Form 4
Chan Frank
EVP, Chief Operating Officer
Transactions
- Tax Payment
Common Stock
[F1][F2]2026-05-15$56.29/sh−546$30,734→ 5,401 total - Award
Common Stock
[F3][F4][F2]2026-05-15+27,535→ 32,936 total
Footnotes (4)
- [F1]Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
- [F2]This number includes unvested RSUs previously reported, 139 shares acquired by the reporting person on October 31, 2025 under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time, the "ESPP") and 119 shares acquired by the reporting person on April 30, 2026 under the ESPP.
- [F3]The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
- [F4]Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Signature
/s/ Thomas V. Powers, attorney-in-fact for Mr. Chan|2026-05-19